Status:
COMPLETED
DERM NMSC Validation Study
Lead Sponsor:
Skin Analytics Limited
Collaborating Sponsors:
Innovate UK
Conditions:
Non-melanoma Skin Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to establish the effectiveness of an Artificial Intelligence (AI) algorithm (DERM) to determine the presence of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) and frequen...
Detailed Description
DERM, an Artificial Intelligence (AI)-based diagnosis support tool, has been shown to be able to accurately identify Non-melanoma skin cancers (NMSC) and other conditions from historical images of sus...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study,
- Male or Female, aged 18 years or above,
- Have at least suspicious skin lesion which is suitable for photographing (\<15mm, not located on an anatomical site inappropriate to photograph (genitalia, hair-bearing areas, under nails), not previously biopsied, not located in an area of visible scarring or tattooing),
- In the Investigator's opinion, able and willing to comply with all study requirements.
Exclusion
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
Key Trial Info
Start Date :
June 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 16 2022
Estimated Enrollment :
572 Patients enrolled
Trial Details
Trial ID
NCT04116983
Start Date
June 26 2020
End Date
March 16 2022
Last Update
May 18 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Free London NHS Foundation Trust
London, United Kingdom, NW3 2QG
2
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom, NE7 7DN
3
Poole General Hospital
Poole, United Kingdom, BH15 2JB